Ventyx Biosciences(US:VTYX)2025-11-06 21:05Financial Performance - Ventyx reported a net loss of $22.8 million for Q3 2025, a decrease from a net loss of $35.2 million in Q3 2024, representing a 35% improvement year-over-year [10]. - Total operating expenses for Q3 2025 were $24.9 million, compared to $38.6 million in Q3 2024, reflecting a 35% decrease [10]. - The company’s accumulated deficit increased to $631.6 million as of September 30, 2025, compared to $554.3 million at the end of 2024 [20]. - Ventyx's total assets decreased to $211.5 million as of September 30, 2025, from $276.6 million at the end of 2024 [20]. Research and Development - Research and Development (R&D) expenses for Q3 2025 were $17.7 million, down from $30.6 million in Q3 2024, indicating a 42% reduction [10]. - VTX3232 demonstrated an approximately 80% reduction in hsCRP levels within the first week of treatment in a Phase 2 study, with 70% of patients achieving target hsCRP levels of 2 mg/L or lower [4]. - The Phase 2 study of VTX2735 in recurrent pericarditis is expected to report topline data in Q4 2025 [5]. - VTX3232 showed statistically significant reductions in IL-6 to levels associated with reduced cardiovascular risk (IL-6 ≤1.65 ng/L) in the recent Phase 2 study [4]. Cash and Liquidity - Cash, cash equivalents, and marketable securities totaled $192.6 million as of September 30, 2025, expected to fund operations into at least H2 2026 [5]. - General and Administrative (G&A) expenses were $7.2 million for Q3 2025, slightly down from $7.9 million in Q3 2024 [10].